Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-H9 vs Genotropin in adults with growth hormone deficiency
2014-002698-13Phase 2Completed
- Sponsor
- Genexine
- Start
- Dec 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eftansomatropin alfa in adult onset growth hormone deficiency (AGHD) and growth hormone deficiency (GHD) (2 arms), sponsored by Genexine. Primary endpoint: Change in serum IGF-1 levels over time by dose. Started Dec 2014; status: completed.
02
Drugs
eftansomatropin alfa
03
Conditions
adult onset growth hormone deficiency (AGHD)growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2014-002698-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002698-13.